Arnold Library

Influence of oral beclomethasone dipropionate on early non-infectious pulmonary outcomes after allogeneic hematopoietic cell transplantation: results from two randomized trials.

Chien, Jason W. and Sakai, Miwa and Gooley, Ted A. and Schoch, H. Gary and McDonald, George B. (2010) Influence of oral beclomethasone dipropionate on early non-infectious pulmonary outcomes after allogeneic hematopoietic cell transplantation: results from two randomized trials. Bone marrow transplantation, 45. pp. 317-324. ISSN 1476-5365

[img]
Preview
Text (Complete manuscript)
ChienJWBMTManuscript073009.pdf
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (295Kb) | Preview
Article URL: http://www.nature.com/bmt/journal/v45/n2/abs/bmt20...

Abstract

Early non-infectious pulmonary complications represent a significant cause of mortality after hematopoietic cell transplantation (HCT). We tested the hypothesis that oral beclomethasone dipropionate (BDP) is effective for preventing early non-infectious pulmonary complications after allogeneic HCT. We retrospectively reviewed the medical records of 120 patients, 60 in each treatment arm, to identify non-infectious and infectious pulmonary events and pulmonary function test results from all patients who participated in two randomized trials of oral BDP for treatment of acute gastrointestinal GVHD. 17-Beclomethasone monopropionate (17-BMP), the active metabolite of BDP, was evaluated in blood from the right atrium in four patients. Thirty-three of 42 (79%) placebo-treated patients experienced a decrease of the DL(CO) from pretransplant to day 80 after transplant, compared with 27 of 49 (55%) BDP-treated patients (P=0.02). In the first 200 days after randomization, there were no cases of non-infectious pulmonary complications in BDP-treated patients, vs four cases among placebo-treated patients (P=0.04). Levels of 17-BMP were detected in atrial blood at steady state. Delivery of a potent glucocorticoid such as 17-BMP to the pulmonary artery after oral dosing of BDP may be useful in modulating pulmonary inflammation and preventing the development of non-infectious pulmonary complications after allogeneic HCT.Bone Marrow Transplantation advance online publication, 29 June 2009; doi:10.1038/bmt.2009.129.

Item Type: Article
Additional Information: This article is available to subscribers only via the URL above.
DOI: 10.1038/bmt.2009.129
PubMed ID: 19561649
NIHMSID: NIHMS135853
PMCID: PMC2820152
Grant Numbers: P01 CA018029, P30 CA015704-
Keywords or MeSH Headings: * Adolescent * Aged * Beclomethasone/analogs & derivatives * Beclomethasone/blood * Beclomethasone/metabolism * Beclomethasone/therapeutic use* * Child * Female * Graft vs Host Disease/drug therapy* * Hematopoietic Stem Cell Transplantation/adverse effects * Humans * Lung Diseases/chemically induced * Lung Diseases/drug therapy* * Lung Diseases, Fungal/etiology * Male * Middle Aged * Respiratory Function Tests
Subjects: Therapeutics > Transplantation > Stem Cell transplantation
Therapeutics > Drug Therapy
Depositing User: Library Staff
Date Deposited: 31 Jul 2009 16:17
Last Modified: 14 Feb 2012 14:42
URI: http://authors.fhcrc.org/id/eprint/320

Repository Administrators Only

View Item View Item
Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N. PO Box 19024
Seattle, WA 98109

a 501(c)(3) nonprofit organization.

© Terms of Use & Privacy Policy